HORIZON-BREAST06

1. 16:40
   mp.weixin.qq.comPick

   HORIZON-Breast06 Phase 3: Trastuzumab Rezetecan Extends PFS in HER2-Low Advanced Breast Cancer

   The phase 3 HORIZON-Breast06 study of Hengrui Medicine's trastuzumab rezetecan (SHR-A1811) extended progression-free survival in patients with HER2-low advanced breast cancer.

2. 15:23
   x.com

   HORIZON-Breast06 en HER2-low: reducción + ++ del riesgo de progresión, con una actividad q refuerza el papel ADC anti-HER2 más allá del HER2 +++. Habrá q esperar a madurez de OS y
3. 02:58
   x.com

   #ScienceLink #Madrid2026 #ESMO26 #HORIZONBreast06 #Trastuzumabrezetecan
4. 01:09
   x.com

   "PFS chemo-naive: 16.6 vs 6.8 mo HR 0.25" @stolaney1

1. 20:57
   x.com

   Three HER2 ADCs now in HER2-low MBC. At #ESMO26, HORIZON-Breast06 & APEX-Breast01 both beat chemo on PFS (HR ~0.25–0.29). But as @BarbaraPistill2 noted: same payload class as T
2. 20:19
   x.com

   First breast session at #ESMO26 highlights how China is developing novel drugs at rapid speed.
3. 20:14
   mp.weixin.qq.com
4. 20:11
   x.com

   HORIZON-Breast06 confirms benefit of trastuzumab *rezetecan* in a DB06-like patient population—HER2low, chemo-naive
5. 20:07
   x.com

   HORIZON-Breast06:
6. 19:59
   x.com

   Cowabunga! 🌊 Riding the Metastatic Breast Cancer Wave 🏄🏻‍♂️🤙🏻 from #ESMO26
7. 19:59
   mp.weixin.qq.com
8. 19:55
   x.com

   #ESMO26 | HORIZON-Breast06
9. 19:54
   x.com
10. 19:53
    x.com

    🇨🇳HORIZON-Breast06: Trastuzumab rezatecan widely outperformed chemo in endocrine-refractory HR+ MBC (PFS 16.6 vs 6.8 months, HR 0.25, p=0<0.01). Definitely passes the truck test
11. 19:53
    x.com

    HORIZON-Breast06: Trastuzumab rezetecan in metastatic HER2low breast cancer
12. 18:11
    x.com

    #ESMO2026 LBA13: Phase 3 HORIZON-Breast06 — Trastuzumab rezetecan (SHR-A1811) vs chemo in HER2-low advanced breast cancer.
13. 17:40
    mp.weixin.qq.comPick

    Hengrui Reports Phase 3 HORIZON-Breast06: Ruzaltatug Median PFS 16.6 Months in Chemo-Naive HER2-Low Advanced Breast Cancer

    Hengrui Pharma reported Phase 3 HORIZON-Breast06 results for ruzaltatug (SHR-A1811) in HER2-low advanced breast cancer. In chemotherapy-naive patients, median PFS was 16.6 months with ruzaltatug versus 6.8 months in the chemotherapy arm.

14. 14:06
    x.com

    #ESMO26 | HORIZON-Breast06

Heat now 60·Peak in the comparable set 126 (Oct 23 21:00)·Change over 24h in the comparable set -38%·Participants now 17

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.